Neuren Pharmaceuticals Limited (AU:NEU) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neuren Pharmaceuticals Limited has reported a change in Director Joseph Basile’s interest, indicating an on-market acquisition of 6,406 ordinary shares at $15.73 per share, totaling $100,766. This transaction has increased his total holdings to 21,406 shares, with 10,000 direct and 11,406 indirect through a self-managed superannuation fund. There were no changes in the director’s interests in contracts or trades during a closed period.
For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.